< Zurück zu den aktuellen Neuigkeiten & Events

Neuigkeiten

Referral to EPO Enlarged Board of Appeal on “Entitlement to Priority”

Februar 2022

A referral has been made to the Enlarged Board of Appeal (EBA) of the EPO concerning entitlement to priority. T 2719/19 has been consolidated with T 1513/17 and the following questions referred to the EBA:

I. Does the EPC confer jurisdiction on the EPO to determine whether a party validly claims to be a successor in title as referred to in Article 87(1)(b) EPC?

II. If question I is answered in the affirmative:

Can a party B validly rely on the priority right claimed in a PCT-application for the purpose of claiming priority rights under Article 87(1) EPC in the case where

1. a PCT-application designates party A as applicant for the US only and party B as applicant for other designated States including regional European patent protection and

2. the PCT-application claims priority from an earlier patent application that designates party A as the applicant and

3. the priority claimed in the PCT-application is in compliance with Article 4 of the Paris Convention?

Background to the Referral

US priority application US 60/571444 (P1) was filed by 3 inventor applicants: R.P. Rother, H. Wang and Z. Zhong. Subsequently, a PCT application was filed which named R.P. Rother, H. Wang and Z. Zhong as applicants for the USA, whereas it named Alexion Pharmaceuticals and the University of Western Ontario as the applicants for a European patent.

An assignment of the priority rights of the inventors Wang and Zhong to Alexion Pharmaceuticals or the University of Western Ontario had not taken place prior to filing of PCT application; only the priority right of the inventor Rother had been assigned to Alexion Pharmaceuticals.

The validity of the priority claim was subsequently contested because Alexion Pharmaceuticals and the University of Western Ontario were not applicants or successors in title to the priority application since Wang and Zhong had not transferred their priority right at the time of filing.

However, Alexion appealed, arguing that where the applicants for a PCT application were not the same for all designated states, they should nevertheless be regarded as „joint applicants“.

The „joint applicants approach“ is where party A is an applicant for the priority application and parties A and B are applicants for the subsequent application in which the priority right was invoked. Party B can benefit from the priority right to which their co-applicant party A was entitled. A separate transfer of the priority right to party B was not needed. The joint applicants approach was developed in EPO case law and is described in Article 118:

„Where the applicants for or proprietors of a European patent are not the same in respect of different designated Contracting States, they shall be regarded as joint applicants or proprietors for the purposes of proceedings before the European Patent Office. The unity of the application or patent in these proceedings shall not be affected; in particular the text of the application or patent shall be uniform for all designated Contracting States, unless this Convention provides otherwise.“

Alexion’s argument was that the joint applicants approach should also apply to PCT applications. That is, Alexion believed that themselves, The University of Western Ontario, Rother, Wang and Zhong were all joint applicants of the PCT application.

The Board of Appeal particularly noted divergent practice on the PCT joint applicant approach and a number of cases in which the validity the PCT joint applicant approach had or was in dispute (T 2749/18, T 2842/18, T 1837/19 and T 845/19). The Board of Appeal concluded that the issue was a point of law of fundamental importance and therefore deserved a referral to the Enlarged Board of Appeal for guidance on the priority issue. Interestingly, the referred questions included a question on whether the EPO is even competent to determine questions of assignment of the right to priority, as the Board of Appeal also felt there was need for clarification on this issue.


This update was prepared by HGF Professional Standards Officer Dr Edward Pullicino.

Aktuelle Neuigkeiten

Die Beschwerdekammer des EPA äußert sich zum Umfang des Ausschlusses der Sittenwidrigkeit von der Patentierbarkeit

Die jüngste Entscheidung T1553/22 der Beschwerdekammer verpflichtete die Kammer, den Umfang der Ausschlüsse von der Patentierbarkeit gemäß Artikel 53(a) EPÜ zu prüfen. Die Erfindung in diesem Fall bezog sich auf …

Weiterlesen

T1977/22: Can claims defined by open-ended ranges ever be sufficiently disclosed?

The EPO’s Board of Appeal’s decision in T1977/22 provides an interesting review of the case law concerning the compatibility of whole range sufficiency and claims defined as a result to …

Weiterlesen

The draft of The Genetic Technology (Precision Breeding) Regulations 2025 reveals practical details on how to obtain a Precision Bred Organism status

In a recent blog post we discussed the Precision Breeding Regulatory Framework developed by the Food Standards Agency (FSA). Further details on the application process for Precision Bred Organism confirmation …

Weiterlesen

Eine Lehre aus 2,1 Millionen Pfund: Die Macht vertraulicher Informationen

Ein kürzlich ergangenes Urteil des High Court im Vereinigten Königreich1 erinnert uns eindringlich daran, wie wichtig es ist, vertrauliche Geschäftsinformationen zu respektieren. Hambro Perks wurde wegen Verletzung der Vertraulichkeit für …

Weiterlesen
Event - 6. March 2025

IQPC Global IP Exchange Europe 2025

HGF sponsert die IQPC Global IP Exchange Europe, die vom 11. bis 12. März 2025 im Meliá, Berlin, stattfindet. Der Leiter der Elektronikabteilung, Chris Benson, wird die Veranstaltung leiten und …

Veranstaltungsdetails

IP-Zutaten: Das Urteil übergießen: Was Thatchers gegen Aldi für Lebensmittel- und Getränkemarken bedeutet

Leser unseres Blogs „IP Ingredients“ erinnern sich vielleicht daran, dass wir diesen Fall im vergangenen Sommer in unserem Beitrag IP Ingredients: Summer case law review behandelt haben. Der Streit zwischen …

Weiterlesen

Erfindungen in Europa und darüber hinaus schützen

Ein Patent ist eine Form des eingetragenen geistigen Eigentumsrechts, das für neue, erfinderische und gewerblich anwendbare Erfindungen erteilt wird. Patente sind Monopolrechte, die ihrem Inhaber (oder Lizenznehmer) das Recht einräumen, …

Weiterlesen